Sabra Healthcare REIT Inc [SBRA] stock is trading at $16.80, up 1.14%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SBRA shares have gain 1.02% over the last week, with a monthly amount drifted -4.98%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sabra Healthcare REIT Inc [NASDAQ: SBRA] stock has seen the most recent analyst activity on January 07, 2025, when JMP Securities upgraded its rating to a Mkt Outperform but kept the price target unchanged to $20 for it. Previously, Mizuho downgraded its rating to Neutral on December 05, 2024, and kept the price target unchanged to $20. On October 01, 2024, upgrade upgraded it’s rating to Overweight and revised its price target to $20 on the stock. Citigroup upgraded its rating to a Buy and increased its price target to $20 on September 13, 2024. Deutsche Bank initiated its recommendation with a Buy and recommended $21 as its price target on January 30, 2024. BMO Capital Markets downgraded its rating to Market Perform for this stock on October 17, 2023, but kept the price target unchanged to $16. In a note dated October 16, 2023, Wells Fargo upgraded an Equal Weight rating on this stock and boosted its target price from $13 to $15.
Sabra Healthcare REIT Inc [SBRA] stock has fluctuated between $12.83 and $20.03 over the past year. Currently, Wall Street analysts expect the stock to reach $19 within the next 12 months. Sabra Healthcare REIT Inc [NASDAQ: SBRA] shares were valued at $16.80 at the most recent close of the market. An investor can expect a potential return of 13.1% based on the average SBRA price forecast.
Analyzing the SBRA fundamentals
Sabra Healthcare REIT Inc [NASDAQ:SBRA] reported sales of 692.54M for the trailing twelve months, which represents a growth of 8.86%. Gross Profit Margin for this corporation currently stands at 0.52% with Operating Profit Margin at 0.38%, Pretax Profit Margin comes in at 0.14%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.04 and Total Capital is 0.07. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.91.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.59 points at the first support level, and at 16.39 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.94, and for the 2nd resistance point, it is at 17.09.
Ratios To Look Out For
Considering the valuation of this stock, the price to sales ratio is 5.74, the price to book ratio is 1.45 and price to earnings (TTM) ratio is 40.55.
Transactions by insiders
Recent insider trading involved Cusack Catherine, Director, that happened on May 22 ’24 when 7000.0 shares were purchased. Director, FOSTER MICHAEL J completed a deal on May 14 ’24 to sell 10000.0 shares.
